Eli Lilly and Company

Matthew Robert Reinhard

Karin Briner

Christopher Stanley Galka

Maria Angeles Martinez-Grau

John Gordon Allen

Roger Ryan Rothhaar

Leonard Larry Winneroski, Jr

Michael J Rodriguez

Matthew Joseph Fisher

Timothy Paul Burkholder

Joseph P Burkhart

Yanping Xu

Andrew Caerwyn Williams

Frantz Victor

Shawn Christopher Miller

Jeffrey Thomas Mullaney

Deyi Zhang

Michael Wade Tidwell

Michael Philip Mazanetz

William Harlan Gritton

Brian Eugene Cunningham

John M Schaus

Steven Armen Boyd

Julie M Miyashiro

David Andrew Coates

Yao-Chang Xu

Cynthia Darshini Jesudason

Joseph H Krushinski, Jr

Dennis C Thompson

Ajay Singh

Freddie Craig Stevens

Natalia Pokrovskaia

Michael Philip Cohen

Richard Edmund Rathmell

Richard C Hoying

Manuel Javier Cases-Thomas

Selma Sapmaz

Christopher David Beadle

Craig Daniel Wolfangel

John Cunningham O'Toole

Alicia Marcos Llorente

Sarah Lynne Hellman

Junliang Hao

Arundhati S Deo

Christopher Stephen Siedem

Marta Adeva Bartolome

Karen Briner

Wai-Man Lee

Richard Gerard Conway

John Mehnert Schaus

Joseph Herman Krushinski Jr

Michael John Rodriguez

Joseph Herman Krushinski

The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia. 

[object Object]

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is &#x2014;NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification. 

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where:

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: 

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N&#x2014;R&#x2033;R* where R6 is &#x2014;(CrC3)alkyl-S&#x2014;(C0-C3)alkyl-R10, &#x2014;(C1-C3)alkyl-NR11R12, &#x2014;(CrC3)alkyl-O&#x2014;R13. and other substituents are as defined in the specification. 

The present invention provides serotonergic benzofurylpiperazines of Formula I:where:

Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists

The present invention provides serotonergic benzofurans of Formula (I): where A, R, R, R, R, and Rare as described in the specification.

Serotonergic benzofurans

Growing community of inventors

Indianapolis, IN, United States of America

Matthew Robert Reinhard